Evidence map›Paper›PMID 41002422›Full record

ArticleCells2025

Dysregulation of SELENOI Is Associated with TDP-43 Neuropathology in Amyotrophic Lateral Sclerosis.

Finula I Isik, Jasmin Galper, Russell Pickford, Nicolas Dzamko, YuHong Fu, Woojin Scott Kim

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Finula I IsikBrain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0003-2060-1180
Jasmin GalperBrain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0001-7204-2849
Russell PickfordBioanalytical Mass Spectrometry Facility, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0001-8982-7618
Nicolas DzamkoBrain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-9121-0294
YuHong FuBrain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0003-4539-2039
Woojin Scott KimBrain and Mind Centre, The University of Sydney, Sydney, NSW 2006, Australia.ORCID 0000-0002-4707-933X

Funding

Brain Tissue Resource Centre for Alcohol ResearchR28AA012725 · NIAAA · UNIVERSITY OF SYDNEY · PI Greg Trevor Sutherland · 2012 to 2026
$7.0M
FightMND IM-202303-00957NIAAA NIH HHS R28 AA012725
6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease, is characterized by progressive degeneration of motor neurons and accumulation of TAR DNA-binding protein 43 (TDP-43) in the brain. Increasing evidence indicates that aberration in lipid synthesis or regulation underlies neuronal dysfunction and degeneration. Phosphatidylethanolmine (PE) is an abundant phospholipid in the brain and is synthesized by the SELENOI gene. SELENOI is important in motor neuron development and function, as demonstrated in hereditary spastic paraplegia, a neurological disorder in which SELENOI is mutated. Despite this, virtually nothing was known about SELENOI in the context of ALS neuropathology. We therefore undertook a comprehensive assessment of PE in ALS brain tissues, using sophisticated liquid chromatography-mass spectrometry, and investigated how SELENOI regulates TDP-43 expression. PE levels were significantly decreased in the disease-affected motor cortex of ALS compared to controls and were inversely associated with disease duration. In contrast, PE levels were unaltered in the disease-unaffected cerebellum. Consistent with this, SELENOI expression was dysregulated only in the motor cortex of ALS. The correlation between SELENOI and TDP-43 was also lost in the motor cortex of ALS. A knockdown of SELENOI expression in neuronal cells caused an upregulation of TDP-43 expression. When put together, these results suggest that SELENOI dysregulation may contribute to TDP-43 pathology in ALS brain. Our study has provided new insights into an unrecognized pathway in ALS brain and revealed new targets for controlling TDP-43 pathology in ALS brain.

Indexed as

Amyotrophic Lateral SclerosisDNA-Binding ProteinsAgedBrainFemaleHumansMaleMiddle AgedMotor CortexMotor NeuronsDNA-Binding ProteinsTARDBP protein, humanamyotrophic lateral sclerosismotor cortexmotor neuron diseasephosphatidylethanolmineSELENOITDP-43

Identifiers

PMID41002422
PMCPMC12469239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.